Abstract
Determining which features drive the treatment effect for individual patients has long been a complex and critical question in clinical decision-making. Evidence from randomized controlled trials (RCTs) are the gold standard for guiding treatment decisions. However, individual patient differences often complicate the application of RCT findings, leading to imperfect treatment options. Traditional subgroup analyses fall short due to data dimensionality, type, and study design. To overcome these limitations, we propose CODE-XAI, a framework that interprets Conditional Average Treatment Effect (CATE) models using Explainable AI (XAI) to perform feature discovery. CODE-XAI provides feature attribution at the individual subject level, enhancing our understanding of treatment responses. We benchmark these XAI methods using semi-synthetic data and RCTs, demonstrating their effectiveness in uncovering feature contributions and enabling cross-cohort analysis, advancing precision medicine and scientific discovery.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The survey data for this study was gathered under an exempt determination from the University of Washington Institutional Review Board (Human Subjects Division, STUDY00006890). All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* indicates co-senior authorship
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos